Bladder cancer is most often associated with Smoking and exposure to carcinogenic substances in the workplace. This disease is one of the top 10 most common cancers in men and women in the United States, and more than 70 percent of the disease bladder cancer is diagnosed in stage T1. At these early stages, the standard treatment is surgery (transurethral resection) and the burning of tumors with high energy (glare). Many patients can also receive subsequent intravesical chemotherapy, because very often there is a high risk of cancer recurrence.
"Interestingly, our bodies can naturally identify, in response to kill tumor cells," explains doctor of medicine and a leading American oncologist William Larchian. "We are developing a system of vaccination on how to improve this treatment method against existing and future cell tumors of the bladder in patients with bladder cancer". Dr. Marchiano and his colleagues were able to develop an effective system that reliably introduces multiple copies of the IL-2 DNA in the cells of bladder cancer. "This method allows you to make more copies of the gene to enter the cell tumors," said he, "and we can observe a higher level of transfection compared to retroviral methods."
Other studies Dr. Lerchiana and his colleagues intend to use further work on the development of gene therapy systems, which can be used for delivery of other key genes of defense against bladder cancer. Dr. Larian currently also developing a system using nanoparticles for the treatment of bladder cancer.